Allergen for Birch Pollen Allergy is under clinical development by Roxall Medizin and currently in Phase II for Birch Pollen Allergy. According to GlobalData, Phase II drugs for Birch Pollen Allergy does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Allergen for Birch Pollen Allergy LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Allergen for Birch Pollen Allergy overview

Allergen is under development for the treatment of allergic rhinitis and rhino-conjunctivitis caused by birch pollen allergy. The therapeutic candidate is administered through subcutaneous route as suspension. It is also administered through sublingual route as spray or solution.

Roxall Medizin overview

Roxall Medizin (Roxall) is a manufacturer and distributor of pharmaceutical products. The company develops products in allergology, immunology and emergency medicine fields. Its products include CLUSTO-Prick and Prixi. Its CLUSTO-Prick product operates as a medical device for in-vivo diagnostic of allergic diseases and provides automated system for skin prick tests. Roxall also provides pharmaceutical products for therapy of poisoning emergencies. The company offers allergy services to the allergologically operating specialist and clinics. It also provides biologically and biochemically standardized allergen extracts for diagnosis and treatment. Roxall is headquartered in Oststeinbek, Hamburg, Germany.

For a complete picture of Allergen for Birch Pollen Allergy’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.